The Ret gene products include two glycosylated proteins and, in tunicamycin treated cells, a non-glycosylated protein consistent with the predicted Ret molecular weight based on sequence analysis.
Tumor-specific rearrangements of the Ret proto-oncogene have been identified in papillary thyroid carcinomas leading to the formation of different transforming fusion proteins sharing the tyrosine kinase domain of Ret.
In contrast to the Ret proto-oncogene, the rearranged forms are constitutively phosphorylated on tyrosine and are translocated from the membrane to the cytoplasm.
Applications:Suitable for use in Western Blot, Immunohistochemistry.
Other applications not tested.
Recommended Dilution:Western Blot: 1:500-1:1000Immunohistochemistry: 1:50-1:200Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20°C.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size:50ul
Host:rabbit
Source Antibody:human
Grade:Affinity Purified
Purity:Purified by immunoaffinity chromatography.
Form:Supplied as a liquid PBS, 0.05% sodium azide, pH 7.2.
Specificity:Recognizes endogenous levels of Ret, phosphorylated Y1062. Species Crossreactivity: Human, mouse, rat
Isotype:IgG
Calc Applications Abbrev:IHC WB
Calc Crossreactivity:Hu Mo Rt
Immunogen:Synthetic phosphopeptide derived from human Ret around the phosphorylation site of Tyrosine 1062.